RU2015108348A - Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения - Google Patents
Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения Download PDFInfo
- Publication number
- RU2015108348A RU2015108348A RU2015108348/10A RU2015108348A RU2015108348A RU 2015108348 A RU2015108348 A RU 2015108348A RU 2015108348/10 A RU2015108348/10 A RU 2015108348/10A RU 2015108348 A RU2015108348 A RU 2015108348A RU 2015108348 A RU2015108348 A RU 2015108348A
- Authority
- RU
- Russia
- Prior art keywords
- loxl
- antibody
- access number
- rpds
- monoclonal anti
- Prior art date
Links
- 239000012634 fragment Substances 0.000 claims abstract 34
- 239000000427 antigen Substances 0.000 claims abstract 28
- 102000036639 antigens Human genes 0.000 claims abstract 28
- 108091007433 antigens Proteins 0.000 claims abstract 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 3
- 230000002255 enzymatic effect Effects 0.000 claims abstract 2
- 229920001184 polypeptide Polymers 0.000 claims abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 239000000523 sample Substances 0.000 claims 9
- 101001043352 Homo sapiens Lysyl oxidase homolog 2 Proteins 0.000 claims 5
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 claims 5
- 206010027476 Metastases Diseases 0.000 claims 5
- 206010016654 Fibrosis Diseases 0.000 claims 4
- 230000033115 angiogenesis Effects 0.000 claims 4
- 230000004761 fibrosis Effects 0.000 claims 4
- 230000009401 metastasis Effects 0.000 claims 4
- 239000013068 control sample Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 2
- 230000012010 growth Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000001093 anti-cancer Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 229920001059 synthetic polymer Polymers 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000005747 tumor angiogenesis Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30155010P | 2010-02-04 | 2010-02-04 | |
| US61/301,550 | 2010-02-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012137515/10A Division RU2549684C2 (ru) | 2010-02-04 | 2011-02-04 | Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015108348A true RU2015108348A (ru) | 2015-07-20 |
Family
ID=44355814
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015108348/10A RU2015108348A (ru) | 2010-02-04 | 2011-02-04 | Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения |
| RU2012137515/10A RU2549684C2 (ru) | 2010-02-04 | 2011-02-04 | Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012137515/10A RU2549684C2 (ru) | 2010-02-04 | 2011-02-04 | Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8680246B2 (OSRAM) |
| EP (1) | EP2531217A4 (OSRAM) |
| JP (2) | JP6134142B2 (OSRAM) |
| KR (1) | KR20130008021A (OSRAM) |
| CN (2) | CN103370080A (OSRAM) |
| AU (1) | AU2011212830B2 (OSRAM) |
| BR (1) | BR112012019693A2 (OSRAM) |
| CA (1) | CA2789022A1 (OSRAM) |
| IL (1) | IL221245A0 (OSRAM) |
| MX (1) | MX2012009088A (OSRAM) |
| NZ (1) | NZ601615A (OSRAM) |
| RU (2) | RU2015108348A (OSRAM) |
| SG (1) | SG183174A1 (OSRAM) |
| WO (1) | WO2011097513A1 (OSRAM) |
| ZA (1) | ZA201306608B (OSRAM) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030114410A1 (en) | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
| WO2009017833A2 (en) | 2007-08-02 | 2009-02-05 | Arresto Biosciences | Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis |
| US9107935B2 (en) | 2009-01-06 | 2015-08-18 | Gilead Biologics, Inc. | Chemotherapeutic methods and compositions |
| WO2011022667A2 (en) | 2009-08-21 | 2011-02-24 | Arresto Biosciences, Inc | Catalytic domains from lysyl oxidase and loxl2 |
| WO2011022670A1 (en) * | 2009-08-21 | 2011-02-24 | Arresto Biosciences, Inc | In vivo screening assays |
| EP2531217A4 (en) | 2010-02-04 | 2013-11-27 | Gilead Biologics Inc | ANTIBODIES THAT BIND TO LOXL2 (LYSYL OXIDASE-LIKE 2) AND METHODS OF USE THEREOF |
| AU2012261883A1 (en) * | 2011-06-01 | 2013-05-02 | Gilead Biologics, Inc. | Lysyl oxidase-like 2 assay and methods of use thereof |
| CA2865501A1 (en) | 2012-02-29 | 2013-09-06 | Gilead Biologics, Inc. | Antibodies to matrix metalloproteinase 9 |
| EP2901163B1 (en) * | 2012-09-28 | 2018-11-28 | Case Western Reserve University | Method for detecting lysyl oxidase-like 2 protein (loxl2) and breast cancer |
| SG11201503065PA (en) | 2012-10-30 | 2015-05-28 | Gilead Sciences Inc | Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2) |
| WO2014130758A1 (en) * | 2013-02-22 | 2014-08-28 | The Trustees Of Columbia Unversity In The City Of New York | Compositions and methods for inhibiting tumor cells by inhibiting the transcription factor atf5 |
| US11059906B2 (en) * | 2013-05-23 | 2021-07-13 | Takeda Pharmaceutical Company Limited | Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma |
| US20150148345A1 (en) | 2013-11-26 | 2015-05-28 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
| US20160331754A1 (en) | 2014-01-20 | 2016-11-17 | Gilead Sciences, Inc. | Therapies for treating cancers |
| WO2015187499A1 (en) | 2014-06-03 | 2015-12-10 | Gilead Sciences, Inc. | Use of an ask1 inhibitor for the treatment of liver disease, optionally in combination with a loxl2 inhibitor |
| CN106456772A (zh) | 2014-06-11 | 2017-02-22 | 吉利德科学公司 | 用于治疗心血管疾病的方法 |
| US10040868B2 (en) * | 2014-07-24 | 2018-08-07 | Yeda Research And Development Co. Ltd. | Antibodies targeted against LOXL-2 for the treatment of collagen-associated pathologies |
| TW201639573A (zh) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
| EP3722297A1 (en) | 2015-03-04 | 2020-10-14 | Gilead Sciences, Inc. | Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds |
| KR102594441B1 (ko) | 2015-03-06 | 2023-10-25 | 파마케아, 인크. | 플루오르화된 리실 옥시다아제-유사 2 억제제 및 이의 용도 |
| CN104792998B (zh) * | 2015-03-09 | 2016-06-08 | 中国人民解放军第四军医大学 | Loxl2抗原用于制备甲状腺癌预示、侵袭、转移试剂盒的应用 |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| RS64397B1 (sr) | 2015-03-27 | 2023-08-31 | Immatics Biotechnologies Gmbh | Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv raznih tumora (seq id 25 - mrax5-003) |
| JP2018530550A (ja) | 2015-10-01 | 2018-10-18 | ギリアド サイエンシズ， インコーポレイテッド | 癌を治療するためのｂｔｋ阻害剤とチェックポイント阻害剤との組合せ |
| JP2019500368A (ja) | 2015-12-17 | 2019-01-10 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔａｎｋ結合キナーゼ阻害剤化合物 |
| AU2017228371A1 (en) | 2016-03-04 | 2018-09-13 | Gilead Sciences, Inc. | Compositions and combinations of autotaxin inhibitors |
| US20170306050A1 (en) | 2016-04-08 | 2017-10-26 | Gilead Sciences, Inc. | Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases |
| US10059769B2 (en) | 2016-06-13 | 2018-08-28 | I-Mab | Anti-PD-L1 antibodies and uses thereof |
| AU2017305303B2 (en) | 2016-08-04 | 2020-05-28 | Gilead Sciences, Inc. | Cobicistat for use in cancer treatments |
| US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| ES2906581T3 (es) | 2016-09-02 | 2022-04-19 | Gilead Sciences Inc | Compuestos moduladores de los receptores tipo Toll |
| BR112019004513A2 (pt) * | 2016-09-07 | 2019-06-18 | Pharmakea Inc | usos de um inibidor de lisil oxidase-like 2 |
| AU2017324445A1 (en) | 2016-09-07 | 2019-04-11 | Pharmakea, Inc. | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making |
| WO2018085069A1 (en) | 2016-11-03 | 2018-05-11 | Gilead Sciences, Inc. | Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer |
| WO2018097977A1 (en) | 2016-11-22 | 2018-05-31 | Gilead Sciences, Inc. | Crystalline forms of a phosphate complex of a bet inhibitor |
| WO2018137598A1 (en) | 2017-01-24 | 2018-08-02 | I-Mab | Anti-cd73 antibodies and uses thereof |
| US10316077B2 (en) | 2017-02-20 | 2019-06-11 | Sapience Therapeutics, Inc. | Cell-penetrating ATF5 polypeptides and uses thereof |
| TWI754011B (zh) | 2017-02-24 | 2022-02-01 | 美商基利科學股份有限公司 | 布魯頓氏酪胺酸激酶之抑制劑 |
| US10314844B2 (en) | 2017-02-24 | 2019-06-11 | Gilead Sciences, Inc. | Inhibitors of Bruton's tyrosine kinase |
| GB201704206D0 (en) * | 2017-03-16 | 2017-05-03 | Nordic Bioscience As | Lysyl oxidase like-2 assay |
| US10941178B2 (en) * | 2017-03-17 | 2021-03-09 | Gilead Sciences, Inc. | Method of purifying an antibody |
| BR112019021056B1 (pt) | 2017-04-06 | 2022-11-22 | Sustain Holdings, Llc | Usos de uma composição que compreende um peptídeo mimético de colágeno para o tratamento ou a prevenção de uma doença, distúrbio ou ferida ocular |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| CN111566120B (zh) | 2017-12-20 | 2023-09-29 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸 |
| EP3728282B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| US10525100B2 (en) | 2018-01-03 | 2020-01-07 | Sapience Therapeutics, Inc. | ATF5 peptide variants and uses thereof |
| CN111712494A (zh) | 2018-02-13 | 2020-09-25 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| EP4600247A3 (en) | 2018-04-19 | 2025-11-19 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| EP3814272A4 (en) | 2018-05-11 | 2022-03-02 | Phosphorex, Inc. | Microparticles and nanoparticles having negative surface charges |
| CN112118845B (zh) | 2018-05-14 | 2023-06-13 | 吉利德科学公司 | Mcl-1抑制剂 |
| KR20230159715A (ko) | 2018-07-13 | 2023-11-21 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| US11179397B2 (en) | 2018-10-03 | 2021-11-23 | Gilead Sciences, Inc. | Imidazopyrimidine derivatives |
| AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| CN113227089B (zh) | 2018-10-31 | 2024-07-05 | 吉利德科学公司 | 作为hpk1抑制剂的取代的6-氮杂苯并咪唑化合物 |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| US11389513B2 (en) | 2019-04-22 | 2022-07-19 | Sustain Holdings, Llc | Collagen peptide-based medicament compositions and devices and methods of production and use thereof |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| CA3140708A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| JP7295283B2 (ja) | 2019-06-25 | 2023-06-20 | ギリアード サイエンシーズ， インコーポレイテッド | Ｆｌｔ３ｌ－ｆｃ融合タンパク質及び使用方法 |
| US11697807B2 (en) | 2019-09-30 | 2023-07-11 | Case Western Reserve University | Electrochemical biosensor |
| TWI832035B (zh) | 2020-02-14 | 2024-02-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| US20230301950A1 (en) | 2020-06-26 | 2023-09-28 | Raqualia Pharma Inc. | Method for selecting cancer patients for whom combination therapy with retinoid and cancer therapeutic agent is effective, and combination medicament with retinoid and cancer therapeutic agent |
| US11883432B2 (en) | 2020-12-18 | 2024-01-30 | Century Therapeutics, Inc. | Chimeric antigen receptor system with adaptable receptor specificity |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| AU2022419982A1 (en) | 2021-12-22 | 2024-06-06 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ｉｋａｒｏｓ鋅指家族降解劑及其用途 |
| PE20250157A1 (es) | 2022-04-21 | 2025-01-22 | Gilead Sciences Inc | Compuestos de modulacion de kras g12d |
| CN114965818B (zh) * | 2022-05-30 | 2023-05-30 | 广东产品质量监督检验研究院（国家质量技术监督局广州电气安全检验所、广东省试验认证研究院、华安实验室） | 一种降尿酸、痛风类功能食品中非法添加药物的检测方法 |
| CN119384415A (zh) | 2022-07-01 | 2025-01-28 | 吉利德科学公司 | Cd73化合物 |
| US20240254118A1 (en) | 2022-12-22 | 2024-08-01 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| KR20250167002A (ko) | 2023-04-11 | 2025-11-28 | 길리애드 사이언시즈, 인코포레이티드 | Kras 조절 화합물 |
| CN121079300A (zh) | 2023-04-21 | 2025-12-05 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN120535638A (zh) * | 2025-05-26 | 2025-08-26 | 中国医学科学院阜外医院 | 一种抗泛赖氨酸氧化酶家族纳米抗体或抗原结合片段与应用 |
Family Cites Families (153)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| DE3164437D1 (en) | 1980-08-25 | 1984-08-02 | Kabivitrum Ab | Peptide substrates for determination of protease activity |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| DE3278334D1 (en) | 1981-10-23 | 1988-05-19 | Genetics Int Inc | Sensor for components of a liquid mixture |
| US4485088A (en) | 1982-03-26 | 1984-11-27 | Bio-Products, Inc. | Method of treatment of fibrotic lesions by topical administration of lathyrogenic drugs |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| ATE45735T1 (de) | 1984-12-22 | 1989-09-15 | Thomae Gmbh Dr K | Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel. |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4627445A (en) | 1985-04-08 | 1986-12-09 | Garid, Inc. | Glucose medical monitoring system |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5182297A (en) | 1988-02-25 | 1993-01-26 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US4965288A (en) | 1988-02-25 | 1990-10-23 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US4943593A (en) | 1988-02-25 | 1990-07-24 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5252608A (en) | 1988-02-25 | 1993-10-12 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5021456A (en) | 1988-02-25 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5059714A (en) | 1988-02-25 | 1991-10-22 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5021404A (en) | 1988-04-20 | 1991-06-04 | The Children's Medical Center Corporation | Angiostatic collagen modulators |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5120764A (en) | 1988-11-01 | 1992-06-09 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| CA2006008C (en) | 1988-12-20 | 2000-02-15 | Donald J. Kessler | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5262035A (en) | 1989-08-02 | 1993-11-16 | E. Heller And Company | Enzyme electrodes |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US4997854A (en) | 1989-08-25 | 1991-03-05 | Trustees Of Boston University | Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5641484A (en) | 1990-12-04 | 1997-06-24 | Board Of Regents, The University Of Texas System | Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen |
| US6933286B2 (en) | 1991-03-19 | 2005-08-23 | R. Martin Emanuele | Therapeutic delivery compositions and methods of use thereof |
| US20020123476A1 (en) | 1991-03-19 | 2002-09-05 | Emanuele R. Martin | Therapeutic delivery compositions and methods of use thereof |
| US6235887B1 (en) | 1991-11-26 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US6015562A (en) | 1992-09-22 | 2000-01-18 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
| US5721138A (en) | 1992-12-15 | 1998-02-24 | Sandford University | Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use |
| US5807718A (en) | 1994-12-02 | 1998-09-15 | The Scripps Research Institute | Enzymatic DNA molecules |
| US5935860A (en) | 1995-03-07 | 1999-08-10 | The George Washington University | Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia |
| AU724579B2 (en) | 1996-04-01 | 2000-09-28 | Sankyo Company Limited | Anti-Fas recombinant antibodies and DNA therefor |
| AUPO156596A0 (en) | 1996-08-09 | 1996-09-05 | University Of Sydney, The | Synthetic polynucleotides |
| DK0958495T3 (da) | 1997-02-06 | 2003-03-10 | Therasense Inc | In vitro analysand sensor med lille volumen |
| AU6468998A (en) | 1997-03-19 | 1998-10-12 | Board Of Trustees Of The University Of Arkansas, The | Compositions and method for the early diagnosis of ovarian cancer |
| NZ515955A (en) | 1997-08-08 | 2003-04-29 | Univ California | Hybridoma producing a monoclonal antibody against beta-6 integrin |
| US6277622B1 (en) | 1997-08-11 | 2001-08-21 | The University Of Sydney | Synthetic polynucleotides |
| US6225118B1 (en) | 1997-10-01 | 2001-05-01 | Biocure Limited | Multicellular in vitro assay of angiogenesis |
| AU734476B2 (en) | 1997-11-05 | 2001-06-14 | Baylor College Of Medicine | Sequences for targeting metastatic cells |
| US6300092B1 (en) | 1999-01-27 | 2001-10-09 | Millennium Pharmaceuticals Inc. | Methods of use of a novel lysyl oxidase-related protein |
| US20020072089A1 (en) | 1999-11-23 | 2002-06-13 | Holtzman Douglas A. | Novel ITALY, Lor-2, STRIFE, TRASH, BDSF, LRSG, and STMST protein and nucleic acid molecules and uses therefor |
| US6140056A (en) | 1999-01-27 | 2000-10-31 | Millennium Pharmaceuticals, Inc. | MSP-18 protein and nucleic acid molecules and uses therefor |
| US20040058355A1 (en) | 1998-09-30 | 2004-03-25 | Millennium Pharmaceuticals, Inc. | Novel 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, H1983, M1983, 38555 or 593 molecules and uses therefor |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US7108982B1 (en) | 1999-02-19 | 2006-09-19 | University Of Iowa Research Foundation | Diagnostics and the therapeutics for macular degeneration |
| US20030149997A1 (en) | 1999-02-19 | 2003-08-07 | Hageman Gregory S. | Diagnostics and therapeutics for arterial wall disruptive disorders |
| US20030152926A1 (en) | 1999-08-11 | 2003-08-14 | Eos Biotechnology, Inc. | Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
| GB0001309D0 (en) | 2000-01-20 | 2000-03-08 | Nestle Sa | Valve arrangement |
| US6808707B2 (en) | 2000-02-04 | 2004-10-26 | Matrix Design | Wound healing compositions and methods using tropoelastin and lysyl oxidase |
| EP1328630A2 (en) | 2000-04-14 | 2003-07-23 | Incyte Genomics, Inc. | Secreted proteins |
| AU2001261194A1 (en) * | 2000-05-03 | 2001-11-12 | University Of Hawaii | Novel members of the lysyl oxidases family of amine oxidases related applications |
| US7700359B2 (en) | 2000-06-02 | 2010-04-20 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells |
| GB0014185D0 (en) | 2000-06-09 | 2000-08-02 | Novartis Res Found | Compound and method |
| US20090233270A9 (en) | 2000-08-02 | 2009-09-17 | St Croix Brad | Secreted and cytoplasmic tumor endothelial markers |
| US20030114410A1 (en) | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
| ATE364087T1 (de) | 2000-08-08 | 2007-06-15 | Wyeth Corp | Regulierung der expression von eer-7, ein mitglied der lysyl oxidase genfamilie, durch oestrogenrezeptoren |
| EP1315519B1 (en) | 2000-08-08 | 2010-12-29 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for treating cancer or liver fibrosis |
| US20020156263A1 (en) | 2000-10-05 | 2002-10-24 | Huei-Mei Chen | Genes expressed in breast cancer |
| AU2002241520A1 (en) | 2000-11-28 | 2003-03-03 | University Of Cincinnati | Blood assessment of injury |
| US7112668B2 (en) | 2001-01-23 | 2006-09-26 | Curagen Corporation | Polypeptides and nucleic acids encoded thereby |
| US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
| US20020182274A1 (en) | 2001-03-21 | 2002-12-05 | Kung-Ming Lu | Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract |
| US20030211076A1 (en) | 2001-05-10 | 2003-11-13 | Wande Li | Compositions and methods for treatment of proliferative disorders |
| US20030092037A1 (en) | 2001-07-18 | 2003-05-15 | Osamu Matsuzaki | Elk1 phosphorylation related gene |
| FR2828206B1 (fr) | 2001-08-03 | 2004-09-24 | Centre Nat Rech Scient | Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire |
| US20030129672A1 (en) | 2001-08-29 | 2003-07-10 | Dyer Richard Dennis | Method for identifying metalloenzyme inhibitors |
| US20040248835A1 (en) | 2001-10-26 | 2004-12-09 | Anja Krebs | Use of a double-stranded ribonucleic acid for treating an infection with a positivestrand rna-virus |
| KR100450950B1 (ko) | 2001-11-29 | 2004-10-02 | 삼성전자주식회사 | 구내/공중망 무선 패킷데이터 서비스를 받는 이동단말기의 인증 방법 및 그 사설망 시스템 |
| EP1455813B1 (en) | 2001-12-18 | 2015-07-15 | mondoBIOTECH AG | Interferon gamma in combination with a diagnostic array for use in the improved treatment of idiopathic pulmonary fibrosis |
| US7186540B2 (en) | 2001-12-27 | 2007-03-06 | National Institute of Advanced Indusrtial Science and Technology | Thermostable glutaminase and thermostable glutaminase gene |
| US20060088532A1 (en) | 2002-03-07 | 2006-04-27 | Kari Alitalo | Lymphatic and blood endothelial cell genes |
| US7655397B2 (en) | 2002-04-25 | 2010-02-02 | The United States Of America As Represented By The Department Of Health And Human Services | Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers |
| WO2004002427A2 (en) | 2002-06-27 | 2004-01-08 | The General Hospital Corporation | Methods for the treatment or prevention of obesity |
| EP2236614A3 (en) | 2002-08-15 | 2011-01-26 | Genzyme Corporation | Brain endothelial cell expression patterns |
| CA2881743A1 (en) | 2002-09-25 | 2004-04-08 | University Of Massachusetts | In vivo gene silencing by chemically modified and stable sirna |
| US20050260639A1 (en) | 2002-09-30 | 2005-11-24 | Oncotherapy Science, Inc. | Method for diagnosing pancreatic cancer |
| US20050259483A1 (en) | 2002-09-30 | 2005-11-24 | Oncotherapy Science, Inc. | Genes and polypeptides relating to prostate cancers |
| WO2004048938A2 (en) | 2002-11-26 | 2004-06-10 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
| AU2003298873B2 (en) | 2002-12-06 | 2011-09-01 | Millennium Pharmaceuticals, Inc. | Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy |
| EP1998177A3 (en) | 2003-01-06 | 2009-02-18 | Wyeth | Compositions and methods for diagnosing and treating colon cancers |
| WO2004063355A2 (en) | 2003-01-10 | 2004-07-29 | Protein Design Labs, Inc. | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer |
| US7393531B2 (en) | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
| CN1759122B (zh) | 2003-03-03 | 2012-06-13 | 得克萨斯州大学系统董事会 | 包含mda-7的组合物和方法 |
| US8383158B2 (en) | 2003-04-15 | 2013-02-26 | Abbott Cardiovascular Systems Inc. | Methods and compositions to treat myocardial conditions |
| NZ543751A (en) | 2003-05-23 | 2008-05-30 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumors of glial origin |
| AU2004256425A1 (en) | 2003-06-09 | 2005-01-20 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| FR2855969B1 (fr) | 2003-06-13 | 2012-11-30 | Coletica | Stimulation de l'activite d'une isoforme de lysyl oxydase pour lutter contre certaines pathologies dues a une elastogenese incomplete, absente ou desorganisee |
| FR2855968B1 (fr) | 2003-06-13 | 2012-11-30 | Coletica | Stimulation de la synthese et de l'activite d'une isoforme de la lysyl oxydase-like loxl pour stimuler la formation de fibres elastiques |
| US10179935B2 (en) | 2003-07-17 | 2019-01-15 | Pacific Edge Limited | Markers for detection of gastric cancer |
| WO2005025596A1 (en) | 2003-09-16 | 2005-03-24 | Hadasit Medical Research Services & Development Ltd. | Glatiramer acetate for use as an immuno-modulatory agent |
| US20080075712A1 (en) | 2003-10-14 | 2008-03-27 | Kunihiro Hattori | Double Specific Antibodies Substituting For Functional Proteins |
| JP4411280B2 (ja) | 2003-10-20 | 2010-02-10 | 帝人ファーマ株式会社 | 骨及び／又は関節疾患関連遺伝子 |
| US20070054278A1 (en) | 2003-11-18 | 2007-03-08 | Applera Corporation | Polymorphisms in nucleic acid molecules encoding human enzyme proteins, methods of detection and uses thereof |
| TW200530269A (en) | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
| US20080261870A1 (en) | 2004-01-13 | 2008-10-23 | Trackman Philip C | Use of the Pro-Peptide Domain of Lysyl Oxidase as a Therapeutic Agent |
| JP2007526247A (ja) | 2004-01-23 | 2007-09-13 | マサチューセッツ・アイ・アンド・イア・インファーマリー | リジルオキシダーゼ様１（ｌｏｘｌ１）および弾性繊維形成 |
| EP1723257B1 (en) | 2004-02-23 | 2019-01-09 | Erasmus University Medical Center Rotterdam | Classification, diagnosis and prognosis of acute myeloid leukemia by gene expression profiling |
| AU2005217623A1 (en) | 2004-02-24 | 2005-09-09 | Attenuon Llp | Inhibition of superoxide dismutase by tetrathiomolybdate: identification of new anti-angiogenic and antitumor agents |
| US20060134172A1 (en) | 2004-12-21 | 2006-06-22 | Alcon, Inc. | Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (LOX) and LOX-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies |
| ES2354267T3 (es) | 2005-02-09 | 2011-03-11 | Arqule, Inc. | Derivados de maleimida, composiciones farmacéuticas y métodos para el tratamiento del cáncer. |
| ATE553122T1 (de) | 2005-02-28 | 2012-04-15 | Sangamo Biosciences Inc | Antiangiogene methoden und zusammensetzungen |
| US20060216722A1 (en) | 2005-03-25 | 2006-09-28 | Christer Betsholtz | Glomerular expression profiling |
| WO2006106823A1 (ja) | 2005-03-31 | 2006-10-12 | Japan Science And Technology Agency | 分子マーカーを用いた間葉系幹細胞の識別方法及びその利用 |
| US8652786B2 (en) | 2005-04-05 | 2014-02-18 | The General Hospital Corporation | Method for predicting responsiveness to drugs |
| US20070021365A1 (en) | 2005-06-21 | 2007-01-25 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of Lysyl oxidase for treating tumor growth and diagnostics relating thereto |
| US20070225242A1 (en) | 2005-06-21 | 2007-09-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method and composition for treating and preventing tumor metastasis in vivo |
| US7846445B2 (en) | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
| US8158107B2 (en) | 2005-09-30 | 2012-04-17 | National Jewish Health | Genes and proteins associated with angiogenesis and uses thereof |
| GB0521139D0 (en) | 2005-10-18 | 2005-11-23 | Univ Sheffield | Therapeutic agent |
| US20090035348A1 (en) | 2005-11-22 | 2009-02-05 | Z & Z Medical Holdings, Inc. | Dissolution of arterial plaque |
| US8445198B2 (en) | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| GB0524991D0 (en) | 2005-12-08 | 2006-01-18 | Ge Healthcare Ltd | Novel imaging agents for fibrosis |
| NZ569234A (en) | 2005-12-09 | 2011-07-29 | Ucb Pharma Sa | Antibody molecules having specificity for human IL-6 |
| WO2007122369A2 (en) | 2006-04-13 | 2007-11-01 | Oncomethylome Sciences Sa | Novel tumour suppressor |
| CN101489394A (zh) * | 2006-04-27 | 2009-07-22 | 小利兰斯坦福大学理事会 | 用于体内治疗和预防肿瘤转移的方法和组合物 |
| US8077896B2 (en) | 2006-12-12 | 2011-12-13 | Sound Services, Llc | Laser inclinometer audio direction |
| KR101443214B1 (ko) | 2007-01-09 | 2014-09-24 | 삼성전자주식회사 | 폐암 환자 또는 폐암 치료를 받은 폐암 환자의 폐암 재발 위험을 진단하기 위한 조성물, 키트 및 마이크로어레이 |
| EP2190448B1 (en) | 2007-06-22 | 2016-04-20 | Children's Medical Center Corporation | Methods and uses thereof of a fragment of saposin a |
| IL184627A0 (en) | 2007-07-15 | 2008-12-29 | Technion Res & Dev Foundation | Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue |
| WO2009017833A2 (en) * | 2007-08-02 | 2009-02-05 | Arresto Biosciences | Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis |
| US8815946B2 (en) | 2008-01-25 | 2014-08-26 | University of Pittsburgh—of the Commonwealth System of Higher Education | Inhibition of proliferation and fibrotic response of activated corneal stromal cells |
| US9107935B2 (en) | 2009-01-06 | 2015-08-18 | Gilead Biologics, Inc. | Chemotherapeutic methods and compositions |
| CA2751438A1 (en) | 2009-02-06 | 2010-08-12 | Arresto Biosciences, Inc. | Methods and compositions for treatment of neovascularization |
| WO2011022670A1 (en) | 2009-08-21 | 2011-02-24 | Arresto Biosciences, Inc | In vivo screening assays |
| EP2467714A4 (en) | 2009-08-21 | 2013-02-20 | Gilead Biologics Inc | IN VITRO SCREENING ASSAYS |
| CN102711821A (zh) | 2009-08-21 | 2012-10-03 | 吉联亚生物科技有限公司 | 治疗方法和组合物 |
| WO2011022667A2 (en) | 2009-08-21 | 2011-02-24 | Arresto Biosciences, Inc | Catalytic domains from lysyl oxidase and loxl2 |
| AU2010284039A1 (en) | 2009-08-21 | 2012-03-22 | Gilead Biologics, Inc. | In vivo screening assays |
| MX2012003759A (es) | 2009-09-29 | 2012-07-23 | Gilead Biologics Inc | Metodos y composiciones para tratamiento de fibrosis ocular. |
| EP2531217A4 (en) | 2010-02-04 | 2013-11-27 | Gilead Biologics Inc | ANTIBODIES THAT BIND TO LOXL2 (LYSYL OXIDASE-LIKE 2) AND METHODS OF USE THEREOF |
| US20140186340A1 (en) | 2011-04-08 | 2014-07-03 | Gilead Biologics, Inc. | Methods and Compositions for Normalization of Tumor Vasculature by Inhibition of LOXL2 |
| AU2012261883A1 (en) | 2011-06-01 | 2013-05-02 | Gilead Biologics, Inc. | Lysyl oxidase-like 2 assay and methods of use thereof |
-
2011
- 2011-02-04 EP EP11740450.9A patent/EP2531217A4/en not_active Withdrawn
- 2011-02-04 RU RU2015108348/10A patent/RU2015108348A/ru not_active Application Discontinuation
- 2011-02-04 NZ NZ601615A patent/NZ601615A/en unknown
- 2011-02-04 RU RU2012137515/10A patent/RU2549684C2/ru active
- 2011-02-04 KR KR1020127023008A patent/KR20130008021A/ko not_active Ceased
- 2011-02-04 CA CA2789022A patent/CA2789022A1/en active Pending
- 2011-02-04 AU AU2011212830A patent/AU2011212830B2/en active Active
- 2011-02-04 US US13/021,555 patent/US8680246B2/en active Active
- 2011-02-04 JP JP2012552118A patent/JP6134142B2/ja active Active
- 2011-02-04 CN CN2011800175320A patent/CN103370080A/zh active Pending
- 2011-02-04 MX MX2012009088A patent/MX2012009088A/es active IP Right Grant
- 2011-02-04 CN CN201610139419.4A patent/CN105622757A/zh active Pending
- 2011-02-04 BR BR112012019693A patent/BR112012019693A2/pt not_active IP Right Cessation
- 2011-02-04 WO PCT/US2011/023791 patent/WO2011097513A1/en not_active Ceased
- 2011-02-04 SG SG2012057816A patent/SG183174A1/en unknown
-
2012
- 2012-08-01 IL IL221245A patent/IL221245A0/en unknown
-
2013
- 2013-09-03 ZA ZA2013/06608A patent/ZA201306608B/en unknown
-
2014
- 2014-02-04 US US14/172,863 patent/US20140302524A1/en not_active Abandoned
- 2014-02-04 US US14/172,864 patent/US20140255951A1/en not_active Abandoned
-
2015
- 2015-08-07 JP JP2015157013A patent/JP2015212304A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NZ601615A (en) | 2014-07-25 |
| IL221245A0 (en) | 2012-10-31 |
| RU2549684C2 (ru) | 2015-04-27 |
| JP2015212304A (ja) | 2015-11-26 |
| MX2012009088A (es) | 2012-12-05 |
| BR112012019693A2 (pt) | 2017-06-20 |
| CA2789022A1 (en) | 2011-08-11 |
| WO2011097513A1 (en) | 2011-08-11 |
| AU2011212830A1 (en) | 2012-08-23 |
| US20140302524A1 (en) | 2014-10-09 |
| US20110200606A1 (en) | 2011-08-18 |
| EP2531217A4 (en) | 2013-11-27 |
| CN105622757A (zh) | 2016-06-01 |
| RU2012137515A (ru) | 2014-03-10 |
| EP2531217A1 (en) | 2012-12-12 |
| AU2011212830B2 (en) | 2014-05-22 |
| JP6134142B2 (ja) | 2017-05-24 |
| CN103370080A (zh) | 2013-10-23 |
| US20140255951A1 (en) | 2014-09-11 |
| US8680246B2 (en) | 2014-03-25 |
| JP2013518903A (ja) | 2013-05-23 |
| ZA201306608B (en) | 2014-06-25 |
| KR20130008021A (ko) | 2013-01-21 |
| SG183174A1 (en) | 2012-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015108348A (ru) | Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения | |
| JP7012360B2 (ja) | 不溶性フィブリンに対する抗体 | |
| JP5219827B2 (ja) | ｉｎｖｉｖｏで抗腫瘍活性を有する抗ヒトＤｌｋ−１抗体 | |
| JP6129305B2 (ja) | Ｃｌｅｃ１４ａに特異性を持つ新規な抗体及びその用途 | |
| US11376333B2 (en) | mTG substrates for covalent conjugation of compounds | |
| JP2015533788A5 (OSRAM) | ||
| JP2016536330A5 (OSRAM) | ||
| MX2014006037A (es) | Anticuerpo anti-trop-2 humano que tiene una actividad antitumoral in vivo. | |
| JP2013522167A (ja) | ｕＰＡＲ結合剤及びその使用方法 | |
| US20150175712A1 (en) | Antagonist to an enzyme and/or a metabolite of the kynurenine pathway | |
| JP6795813B2 (ja) | がん細胞の検出方法、がん細胞内に物質を導入するための試薬、及びがん治療用組成物 | |
| CN107098970A (zh) | 结合细胞内prl‑1多肽或prl‑3多肽的抗体 | |
| KR20140027051A (ko) | 인간 프로스타글란딘 e2 수용체 ep4 에 대한 항체 | |
| EP3123173B1 (en) | Compositions for suppressing cancer by inhibition of tmcc3 | |
| JP2014515600A5 (OSRAM) | ||
| CA2936805A1 (en) | Cell surface prostate cancer antigen for diagnosis | |
| MX2011004945A (es) | Anticuerpos completamente humanos contra n-cadherina. | |
| JPWO2021075545A5 (OSRAM) | ||
| JP2011200233A5 (OSRAM) | ||
| JP2011521619A (ja) | 腫瘍成長、血管新生および転移を妨害する癌標的に対する新規抗体 | |
| WO2011158973A1 (ja) | 新規な抗フィブリン抗体 | |
| WO2016052756A1 (ja) | 浸潤能の高い癌細胞の検出用又は診断用試薬 | |
| RU2706959C2 (ru) | Антитело к igf-1r и его применение для диагностики рака | |
| WO2016167227A1 (ja) | 不溶性フィブリンに対する抗体 | |
| KR20250052374A (ko) | 항-메소텔린 항체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20180312 |